RallybioRLYB
Market Cap: $45.6M
About: Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
Employees: 25
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
5% more funds holding
Funds holding: 62 [Q1] → 65 (+3) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
3.78% less ownership
Funds ownership: 80.08% [Q1] → 76.3% (-3.78%) [Q2]
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
24% less capital invested
Capital invested by funds: $56M [Q1] → $42.4M (-$13.6M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 0 / 0 met price target | 445%upside $6 | Buy Reiterated | 3 Sept 2024 |
Evercore ISI Group Josh Schimmer 62% 1-year accuracy 24 / 39 met price target | 1,264%upside $15 | Outperform Maintained | 26 Aug 2024 |
HC Wainwright & Co. Mitchell Kapoor 0 / 0 met price target | 445%upside $6 | Buy Maintained | 12 Aug 2024 |
Financial journalist opinion
Based on 4 articles about RLYB published over the past 30 days